DNA Oligonucleotide Dry Eye Therapy Bypassing Cold Chain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye, such as anti-inflammatory agents and Janus kinase inhibitors, face challenges including biological contamination risks, antigenicity issues, and the need for cold storage, making them unsuitable for long-term use or topical administration.
Innovation Solution
A dry eye therapeutic agent containing a DNA oligonucleotide that selectively binds to and inhibits IFN-γ, eliminating the risk of biological contamination, allowing storage at room temperature, and providing high solubility and reduced irritability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory agents or Janus kinase inhibitors are used for dry eye treatment, then inflammatory symptoms can be suppressed, but biological contamination risks and antigenicity issues arise
Solution Approach 1:
The patent replaces biological macromolecules (proteins, antibodies) with small molecule Janus kinase inhibitors, substituting a biological system with a chemical system. This eliminates biological contamination risks while maintaining therapeutic effectiveness through targeted inhibition of the Janus kinase signaling pathway involved in inflammatory responses.
Solution Approach 2:
The patent changes the molecular parameters from large biological macromolecules to small synthetic molecules with specific chemical structures. This parameter change from biological to chemical domain resolves the contamination issue while preserving the ability to modulate inflammatory pathways through targeted receptor binding.
2Reliability
If anti-inflammatory agents are administered, then inflammation can be controlled, but antigenicity issues and side effects occur with long-term use
Solution Approach 1:
The patent substitutes protein-based anti-inflammatory agents with synthetic small molecule Janus kinase inhibitors. This replacement eliminates antigenicity since the small molecules are not recognized as foreign proteins by the immune system, enabling safe long-term administration without immune-mediated side effects.
3Reliability
If protein preparations are used for treatment, then therapeutic effects can be achieved, but cold chain storage is required
Solution Approach 1:
The patent replaces temperature-sensitive protein preparations with thermally stable small molecule inhibitors. This substitution eliminates the need for cold chain storage infrastructure, allowing the medication to be stored at ambient temperatures and distributed through常规 pharmaceutical channels.
4Reliability
If instillation treatment is used, then anti-inflammatory effects can be achieved, but treatment time is prolonged and continuation is difficult
Solution Approach 1:
The patent changes the pharmacokinetic parameters by using small molecules with improved absorption, distribution, metabolism, and excretion profiles compared to protein preparations. This enables faster onset of action and sustained therapeutic effects, reducing the overall treatment duration and improving patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNA oligonucleotide effectively inhibits IFN-γ activity, reducing the risk of adverse effects, improving stability and convenience in storage and administration, and providing a long-term solution for dry eye treatment.
Implementation Method 1
a DNA oligonucleotide that selectively binds to IFN-γ
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Provided is a dry eye therapeutic agent that can selectively inhibit IFN-y, have no risk of biological contamination, and can be stored at room temperature. Provided is a dry eye therapeutic agent, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-y. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a large-molecular-weight compound, a biopolymer, or a biocompatible polymer.